| Clinical pharmacology of bivalirudin. | |
| | |
MedLine Citation:
|
PMID: 12064567 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Much progress has been made in understanding and treating acute coronary syndromes. For patients undergoing percutaneous transluminal coronary angioplasty, anticoagulant therapy during the procedure must strike a balance between providing sufficient anticoagulation to prevent thrombus formation and ischemic complications while averting hemorrhagic complications. Bivalirudin, a thrombin-specific anticoagulant, is the only anticoagulant that reduces both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is easy to use, provides predictable anticoagulation, inactivates both free and clot-bound thrombin, and blocks thrombin-mediated platelet activation and aggregation. Drug-drug interaction studies have found no clinically relevant interactions between bivalirudin and ticlopidine, abciximab, tirofiban, or eptifibatide. Bivalirudin is well tolerated by patients who previously received low-molecular-weight heparin (LMWH), when LMWH is discontinued 8-14 hours before bivalirudin is started. Similarly, switching from heparin to bivalirudin at the time of PCI reduces both ischemic and bleeding events. |
| | |
Authors:
|
Michael D Reed; Dawn Bell |
Related Documents
:
|
20655037 - Does warfarin for stroke thromboprophylaxis protect against mi in atrial fibrillation p... 3665957 - Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial ... 7655497 - Portal hypertension associated with anticardiolipin antibodies in a case of systemic lu... 3740157 - Acute myocardial infarction in the puerperium in patients receiving bromocriptine. 15693387 - Acute acalculous cholecystitis following coronary artery bypass surgery. 3883737 - Long-term clinical and hemodynamic results of molsidomine treatment in patients with re... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pharmacotherapy Volume: 22 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 2002 Jun |
Date Detail:
|
Created Date: 2002-06-14 Completed Date: 2003-01-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 105S-111S Citation Subset: IM |
Affiliation:
|
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. mdr2@po.cwru.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina, Unstable
/
therapy Angioplasty, Transluminal, Percutaneous Coronary / adverse effects Anticoagulants / pharmacokinetics, pharmacology*, therapeutic use Antithrombins / pharmacokinetics, pharmacology*, therapeutic use Clinical Trials as Topic Coronary Thrombosis / prevention & control Drug Interactions Fibrinolytic Agents / adverse effects, pharmacology Heparin / adverse effects, pharmacology Hirudins / analogs & derivatives*, pharmacokinetics, pharmacology* Humans Peptide Fragments / pharmacokinetics, pharmacology*, therapeutic use Platelet Aggregation Inhibitors / pharmacology Recombinant Proteins / pharmacokinetics, pharmacology*, therapeutic use Thrombocytopenia / chemically induced Ticlopidine / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Antithrombins; 0/Fibrinolytic Agents; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Aggregation Inhibitors; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 55142-85-3/Ticlopidine; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trends of research and practice in "occupational risk prevention" as seen in Germany.
Next Document: Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients...